124 related articles for article (PubMed ID: 16078846)
1. Development of dual-acting benzofurans for thromboxane A2 receptor antagonist and prostacyclin receptor agonist: synthesis, structure-activity relationship, and evaluation of benzofuran derivatives.
Ohno M; Miyamoto M; Hoshi K; Takeda T; Yamada N; Ohtake A
J Med Chem; 2005 Aug; 48(16):5279-94. PubMed ID: 16078846
[TBL] [Abstract][Full Text] [Related]
2. Development of 3,4-dihydro-2H-benzo[1,4]oxazine derivatives as dual thromboxane A2 receptor antagonists and prostacyclin receptor agonists.
Ohno M; Tanaka Y; Miyamoto M; Takeda T; Hoshi K; Yamada N; Ohtake A
Bioorg Med Chem; 2006 Mar; 14(6):2005-21. PubMed ID: 16297632
[TBL] [Abstract][Full Text] [Related]
3. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
[TBL] [Abstract][Full Text] [Related]
4. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
[TBL] [Abstract][Full Text] [Related]
5. Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compounds.
Takeuchi K; Kohn TJ; True TA; Mais DE; Wikel JH; Utterback BG; Wyss VL; Jakubowski JA
J Med Chem; 1998 Dec; 41(27):5362-74. PubMed ID: 9876106
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pharmacological evaluation of novel nitrobenzenic thromboxane modulators as antiplatelet agents acting on both the alpha and beta isoforms of the human thromboxane receptor.
Hanson J; Reynaud D; Qiao N; Devel P; Moray AL; Renard JF; Kelley LP; Winum JY; Montero JL; Kinsella BT; Pirotte B; Pace-Asciak CR; Dogné JM
J Med Chem; 2006 Jun; 49(12):3701-9. PubMed ID: 16759113
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
[TBL] [Abstract][Full Text] [Related]
8. Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists.
Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee WJ; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Bryant M; Lau J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1544-8. PubMed ID: 16380251
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists.
Asaki T; Hamamoto T; Sugiyama Y; Kuwano K; Kuwabara K
Bioorg Med Chem; 2007 Nov; 15(21):6692-704. PubMed ID: 17764960
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship study on the 6-membered heteroaromatic ring system of diphenylpyrazine-type prostacyclin receptor agonists.
Asaki T; Hamamoto T; Sugiyama Y; Kuwano K; Kuwabara K; Niwa T
Bioorg Med Chem Lett; 2007 Dec; 17(23):6588-92. PubMed ID: 17920266
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP
Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of trimetoquinol derivatives: novel thromboxane A2/prostaglandin H2 antagonists with diminished beta-adrenergic agonist activity.
Christoff JJ; Bradley L; Miller DD; Lei L; Rodriguez F; Fraundorfer P; Romstedt K; Shams G; Feller DR
J Med Chem; 1997 Jan; 40(1):85-91. PubMed ID: 9016331
[TBL] [Abstract][Full Text] [Related]
13. Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities.
Cuisiat S; Bourdiol N; Lacharme V; Newman-Tancredi A; Colpaert F; Vacher B
J Med Chem; 2007 Feb; 50(4):865-76. PubMed ID: 17300168
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and evaluation of nitric oxide releasing derivatives of 3-n-butylphthalide as antiplatelet and antithrombotic agents.
Wang X; Li Y; Zhao Q; Min Z; Zhang C; Lai Y; Ji H; Peng S; Zhang Y
Org Biomol Chem; 2011 Aug; 9(16):5670-81. PubMed ID: 21706121
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.
Gunnet JW; Wines P; Xiang M; Rybczynski P; Andrade-Gordon P; de Garavilla L; Parry TJ; Cheung WM; Minor L; Demarest KT; Maryanoff BE; Damiano BP
Eur J Pharmacol; 2008 Aug; 590(1-3):333-42. PubMed ID: 18599033
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
Dogné JM; Hanson J; de Leval X; Kolh P; Tchana-Sato V; de Leval L; Rolin S; Ghuysen A; Segers P; Lambermont B; Masereel B; Pirotte B
J Pharmacol Exp Ther; 2004 May; 309(2):498-505. PubMed ID: 14742735
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and pharmacological evaluation of 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as novel thromboxane A₂ receptor antagonists.
Bambi-Nyanguile SM; Hanson J; Ooms A; Alpan L; Kolh P; Dogné JM; Pirotte B
Eur J Med Chem; 2013 Jul; 65():32-40. PubMed ID: 23688698
[TBL] [Abstract][Full Text] [Related]
18. Synthetic studies on selective adenosine A2A receptor antagonists. Part II: synthesis and structure-activity relationships of novel benzofuran derivatives.
Saku O; Saki M; Kurokawa M; Ikeda K; Uchida S; Takizawa T; Uesaka N
Bioorg Med Chem Lett; 2010 Jun; 20(12):3768-71. PubMed ID: 20483600
[TBL] [Abstract][Full Text] [Related]
19. A novel antibody targeting the ligand binding domain of the thromboxane A₂ receptor exhibits antithrombotic properties in vivo.
Murad JP; Espinosa EV; Ting HJ; McClure D; Khasawneh FT
Biochem Biophys Res Commun; 2012 May; 421(3):456-61. PubMed ID: 22503974
[TBL] [Abstract][Full Text] [Related]
20. TRA-418, a thromboxane A2 receptor antagonist and prostacyclin receptor agonist, inhibits platelet-leukocyte interaction in human whole blood.
Miyamoto M; Ohno M; Yamada N; Ohtake A; Matsushita T
Thromb Haemost; 2010 Oct; 104(4):788-95. PubMed ID: 20664901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
